# Thryv Holdings, Inc.: financial statements, quarterly

THRY · Nasdaq · CIK 1556739 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/thry.md) · [Financials](/companies/thry/financials.md) · [Filings](/companies/thry/filings.md) · [Insiders](/companies/thry/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/thry/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [184](/filings/0001556739-24-000055.md) | [236 d](/filings/0001556739-26-000013.md) | [234](/filings/0001556739-25-000040.md) | [224](/filings/0001556739-25-000050.md) | [180](/filings/0001556739-25-000072.md) | [187 d](/filings/0001556739-26-000013.md) | [181](/filings/0001556739-26-000028.md) | [210](/filings/0001556739-26-000040.md) | [202](/filings/0001556739-25-000072.md) | [192 d](/filings/0001556739-26-000013.md) | [168](/filings/0001556739-26-000028.md) | [151](/filings/0001556739-26-000040.md) |
| Cost of revenue | $m | [80.2](/filings/0001556739-24-000055.md) | [76.5 d](/filings/0001556739-26-000013.md) | [80.0](/filings/0001556739-25-000040.md) | [75.5](/filings/0001556739-25-000050.md) | [67.9](/filings/0001556739-25-000072.md) | [63.6 d](/filings/0001556739-26-000013.md) | [62.1](/filings/0001556739-26-000028.md) | [63.9](/filings/0001556739-26-000040.md) | [65.1](/filings/0001556739-25-000072.md) | [61.3 d](/filings/0001556739-26-000013.md) | [58.4](/filings/0001556739-26-000028.md) | [56.2](/filings/0001556739-26-000040.md) |
| Gross profit | $m | [104](/filings/0001556739-24-000055.md) | [160 d](/filings/0001556739-26-000013.md) | [154](/filings/0001556739-25-000040.md) | [149](/filings/0001556739-25-000050.md) | [112](/filings/0001556739-25-000072.md) | [123 d](/filings/0001556739-26-000013.md) | [119](/filings/0001556739-26-000028.md) | [147](/filings/0001556739-26-000040.md) | [136](/filings/0001556739-25-000072.md) | [130 d](/filings/0001556739-26-000013.md) | [109](/filings/0001556739-26-000028.md) | [94.6](/filings/0001556739-26-000040.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | [10.2](/filings/0001556739-26-000028.md) | [8.7](/filings/0001556739-26-000040.md) | not reported | not reported | [11.4](/filings/0001556739-26-000028.md) | [7.5](/filings/0001556739-26-000040.md) |
| Operating income | $m | [(19.4)](/filings/0001556739-24-000055.md) | [(242) d](/filings/0001556739-26-000013.md) | [31.1](/filings/0001556739-25-000040.md) | [31.3](/filings/0001556739-25-000050.md) | [(88.6)](/filings/0001556739-25-000072.md) | [(7.2) d](/filings/0001556739-26-000013.md) | [(3.0)](/filings/0001556739-26-000028.md) | [29.5](/filings/0001556739-26-000040.md) | [20.0](/filings/0001556739-25-000072.md) | [10.2 d](/filings/0001556739-26-000013.md) | [4.1](/filings/0001556739-26-000028.md) | [(1.1)](/filings/0001556739-26-000040.md) |
| Interest expense | $m | [15.1](/filings/0001556739-23-000030.md) | [13.8 d](/filings/0001556739-24-000015.md) | [13.4](/filings/0001556739-24-000027.md) | [12.2](/filings/0001556739-25-000050.md) | [11.5](/filings/0001556739-25-000072.md) | [9.7 d](/filings/0001556739-26-000013.md) | [9.1](/filings/0001556739-26-000028.md) | [9.0](/filings/0001556739-26-000040.md) | [8.6](/filings/0001556739-25-000072.md) | [8.1 d](/filings/0001556739-26-000013.md) | [6.6](/filings/0001556739-26-000028.md) | [7.5](/filings/0001556739-26-000040.md) |
| Income tax | $m | [(10.2)](/filings/0001556739-24-000055.md) | [7.9 d](/filings/0001556739-26-000013.md) | [5.4](/filings/0001556739-25-000040.md) | [6.6](/filings/0001556739-25-000050.md) | [(5.4)](/filings/0001556739-25-000072.md) | [1.6 d](/filings/0001556739-26-000013.md) | [(2.9)](/filings/0001556739-26-000028.md) | [8.4](/filings/0001556739-26-000040.md) | [5.8](/filings/0001556739-25-000072.md) | [5.3 d](/filings/0001556739-26-000013.md) | [(6.0)](/filings/0001556739-26-000028.md) | [7.2](/filings/0001556739-26-000040.md) |
| Net income | $m | [(27.0)](/filings/0001556739-24-000055.md) | [(258) d](/filings/0001556739-26-000013.md) | [8.4](/filings/0001556739-25-000040.md) | [5.5](/filings/0001556739-25-000050.md) | [(96.1)](/filings/0001556739-25-000072.md) | [7.9 d](/filings/0001556739-26-000013.md) | [(9.6)](/filings/0001556739-26-000028.md) | [13.9](/filings/0001556739-26-000040.md) | [5.7](/filings/0001556739-25-000072.md) | [(9.7) d](/filings/0001556739-26-000013.md) | [4.5](/filings/0001556739-26-000028.md) | [(16.7)](/filings/0001556739-26-000040.md) |
| Diluted EPS | $ per share | [(0.78)](/filings/0001556739-24-000055.md) | not reported | [0.22](/filings/0001556739-25-000040.md) | [0.15](/filings/0001556739-25-000050.md) | [(2.65)](/filings/0001556739-25-000072.md) | not reported | [(0.22)](/filings/0001556739-26-000028.md) | [0.31](/filings/0001556739-26-000040.md) | [0.13](/filings/0001556739-25-000072.md) | not reported | [0.10](/filings/0001556739-26-000028.md) | [(0.38)](/filings/0001556739-26-000040.md) |
| Basic EPS | $ per share | [(0.78)](/filings/0001556739-24-000055.md) | not reported | [0.24](/filings/0001556739-25-000040.md) | [0.15](/filings/0001556739-25-000050.md) | [(2.65)](/filings/0001556739-25-000072.md) | not reported | [(0.22)](/filings/0001556739-26-000028.md) | [0.32](/filings/0001556739-26-000040.md) | [0.13](/filings/0001556739-25-000072.md) | not reported | [0.10](/filings/0001556739-26-000028.md) | [(0.38)](/filings/0001556739-26-000040.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.7](/filings/0001556739-24-000055.md) | [18.2](/filings/0001556739-25-000015.md) | [14.4](/filings/0001556739-25-000040.md) | [15.5](/filings/0001556739-25-000050.md) | [12.5](/filings/0001556739-25-000072.md) | [16.3](/filings/0001556739-26-000013.md) | [11.0](/filings/0001556739-26-000028.md) | [10.8](/filings/0001556739-26-000040.md) | [11.6](/filings/0001556739-25-000072.md) | [10.8](/filings/0001556739-26-000040.md) | [8.0](/filings/0001556739-26-000028.md) | [9.1](/filings/0001556739-26-000040.md) |
| Current assets | $m | [275](/filings/0001556739-23-000030.md) | [267](/filings/0001556739-25-000015.md) | [275](/filings/0001556739-24-000027.md) | [261](/filings/0001556739-24-000038.md) | [231](/filings/0001556739-24-000055.md) | [211](/filings/0001556739-26-000013.md) | [203](/filings/0001556739-25-000040.md) | [189](/filings/0001556739-25-000050.md) | [194](/filings/0001556739-25-000072.md) | [179](/filings/0001556739-26-000040.md) | [201](/filings/0001556739-26-000028.md) | [158](/filings/0001556739-26-000040.md) |
| Total assets | $m | [1,040](/filings/0001556739-23-000030.md) | [783](/filings/0001556739-25-000015.md) | [787](/filings/0001556739-24-000027.md) | [785](/filings/0001556739-24-000038.md) | [655](/filings/0001556739-24-000055.md) | [712](/filings/0001556739-26-000013.md) | [704](/filings/0001556739-25-000040.md) | [688](/filings/0001556739-25-000050.md) | [702](/filings/0001556739-25-000072.md) | [689](/filings/0001556739-26-000040.md) | [694](/filings/0001556739-26-000028.md) | [654](/filings/0001556739-26-000040.md) |
| Current liabilities | $m | [236](/filings/0001556739-23-000030.md) | [263](/filings/0001556739-25-000015.md) | [240](/filings/0001556739-24-000027.md) | [228](/filings/0001556739-24-000038.md) | [222](/filings/0001556739-24-000055.md) | [196](/filings/0001556739-26-000013.md) | [189](/filings/0001556739-25-000040.md) | [158](/filings/0001556739-25-000050.md) | [169](/filings/0001556739-25-000072.md) | [180](/filings/0001556739-26-000040.md) | [163](/filings/0001556739-26-000028.md) | [158](/filings/0001556739-26-000040.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [311](/filings/0001556739-23-000030.md) | [279](/filings/0001556739-25-000015.md) | [295](/filings/0001556739-24-000027.md) | [290](/filings/0001556739-24-000038.md) | [255](/filings/0001556739-24-000055.md) | [271](/filings/0001556739-26-000013.md) | [273](/filings/0001556739-25-000040.md) | [267](/filings/0001556739-25-000050.md) | [259](/filings/0001556739-25-000072.md) | [236](/filings/0001556739-26-000040.md) | [232](/filings/0001556739-26-000028.md) | [209](/filings/0001556739-26-000040.md) |
| Current portion of debt | $m | [70.0](/filings/0001556739-23-000030.md) | [70.0](/filings/0001556739-25-000015.md) | [52.5](/filings/0001556739-24-000027.md) | [52.5](/filings/0001556739-24-000038.md) | [52.5](/filings/0001556739-24-000055.md) | [13.1](/filings/0001556739-26-000013.md) | [26.3](/filings/0001556739-25-000040.md) | [8.8](/filings/0001556739-25-000050.md) | [8.8](/filings/0001556739-25-000072.md) | [17.5](/filings/0001556739-26-000040.md) | [26.3](/filings/0001556739-26-000028.md) | [35.0](/filings/0001556739-26-000040.md) |
| Shareholders' equity | $m | [397](/filings/0001556739-24-000055.md) | [153](/filings/0001556739-26-000013.md) | [167](/filings/0001556739-25-000050.md) | [183](/filings/0001556739-25-000072.md) | [94.5](/filings/0001556739-25-000072.md) | [197](/filings/0001556739-26-000040.md) | [193](/filings/0001556739-26-000040.md) | [215](/filings/0001556739-26-000040.md) | [221](/filings/0001556739-25-000072.md) | [218](/filings/0001556739-26-000040.md) | [225](/filings/0001556739-26-000040.md) | [212](/filings/0001556739-26-000040.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [45.9 d](/filings/0001556739-24-000055.md) | [44.6 d](/filings/0001556739-26-000013.md) | [5.4](/filings/0001556739-25-000040.md) | [22.2 d](/filings/0001556739-25-000050.md) | [36.0 d](/filings/0001556739-25-000072.md) | [26.1 d](/filings/0001556739-26-000013.md) | [(10.5)](/filings/0001556739-26-000028.md) | [29.6 d](/filings/0001556739-26-000040.md) | [22.2 d](/filings/0001556739-25-000072.md) | [22.2 d](/filings/0001556739-26-000013.md) | [1.5](/filings/0001556739-26-000028.md) | [25.9 d](/filings/0001556739-26-000040.md) |
| Capital expenditure | $m | [8.9 d](/filings/0001556739-24-000055.md) | [10.5 d](/filings/0001556739-26-000013.md) | [7.3](/filings/0001556739-25-000040.md) | [9.0 d](/filings/0001556739-25-000050.md) | [8.5 d](/filings/0001556739-25-000072.md) | [8.8 d](/filings/0001556739-26-000013.md) | [7.1](/filings/0001556739-26-000028.md) | [7.8 d](/filings/0001556739-26-000040.md) | [7.6 d](/filings/0001556739-25-000072.md) | [9.9 d](/filings/0001556739-26-000013.md) | [6.9](/filings/0001556739-26-000028.md) | [9.2 d](/filings/0001556739-26-000040.md) |
| Share repurchases | $m | [0.0 d](/filings/0001556739-24-000055.md) | [0.0 d](/filings/0001556739-26-000013.md) | not reported | not reported | [0.0 d](/filings/0001556739-25-000072.md) | [0.0 d](/filings/0001556739-26-000013.md) | not reported | not reported | [5.0 d](/filings/0001556739-25-000072.md) | [0.0 d](/filings/0001556739-26-000013.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.8](/filings/0001556739-23-000030.md) | [37.0](/filings/0001556739-24-000027.md) | [36.9](/filings/0001556739-24-000038.md) | [34.8](/filings/0001556739-24-000055.md) | [38.0](/filings/0001556739-25-000040.md) | [37.6](/filings/0001556739-25-000050.md) | [36.3](/filings/0001556739-25-000072.md) | [43.4](/filings/0001556739-26-000028.md) | [44.3](/filings/0001556739-26-000040.md) | [44.5](/filings/0001556739-25-000072.md) | [45.2](/filings/0001556739-26-000028.md) | [44.4](/filings/0001556739-26-000040.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 44,439,111 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001556739-26-000040.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.